Fellows of the British Pharmacological Society are members who have demonstrated distinction and peer recognition in pharmacology.
Fellows have made, and may continue to make, substantial contributions to the disciplines of pharmacology, clinical pharmacology and therapeutics, through their work, publication and presentation of research, leadership, and contribution to Society life.
Find out more and apply for Fellowship.
This directory has been created to increase the visibility of our Fellows and their contributions, and to support networking by providing a useful resource for members to connect with Fellows with similar areas of interest.
Here you can find profiles of each Fellow, including information on their institutional affiliation, year elected, primary professional setting, affinity group membership, and a short biography.
Select the magnifying glass icon to begin any searches.
João B Calixto graduated in Biological Sciences and received his PhD in Pharmacology in 1984.
1969-72 BSc (Hons) Physiology & Biochemistry and 1972-75 PhD at University of Southampton.
Meritxell Canals, PhD, is Professor of Molecular and Cellular Pharmacology and Deputy Director of the COMPARE unit at the University of Nottingham.
Dr Carswell graduated in Pharmacy in 1991 from the University of Strathclyde and after her Foundation Pharmacy year at the Glasgow Royal Infirmary, she graduated with a PhD in Neuropharmacology from the University of Glasgow in 1996.
After obtaining his medical degree in Turkey in 1993, Selim completed his PhD in pharmacology at Wellcome Research Laboratories and University College London in 1997 under the supervision of Prof Sir Salvador Moncada.
Steven is Vice President, Pharmacology at OMass Therapeutics, and Professor of Molecular Pharmacology and Drug Discovery in the School of Life Sciences at Nottingham University.
Prabal K “Charley” Chatterjee is a Principal Lecturer in Pharmacology and MSc Pharmacology Course Leader at the University of Brighton.
Sharon is a Director and cofounder of RenaSci Limited, (acquired by the Sygnature Group in 2018) a specialist provider of experimental and consultancy services in the therapeutic areas of metabolic and CNS disorders.